The landscape of bioequivalence guidelines is evolving, with significant progress being made in the ICH M13 guideline series and in global regulatory harmonisation.

While regional/national authorities determine the implementation strategy in their respective regions, Medicines for Europe and the International Generic and Biosimilar medicines Association (IGBA) will gather leading international experts together for the 3^rd Bioequivalence Conference. This is scheduled to take place on 26^th February 2025, at the Hilton Amsterdam Airport Schiphol Hotel, The Netherlands and will be an in-person event.

The conference will provide a platform for an exchange of views between industry, regulators, and academia and will cover the following topics:

• Single global development of generic medicines: enabling patient access
• International harmonisation of bioequivalence: the current status and next steps (ICH M13A implementation and hot topics for M13C)
• Model-informed approaches supporting bioequivalence in generic medicines development
• Data integrity in bioequivalence studies

Join us in Amsterdam in these very special times for bioequivalence and participate in our lively discussions!